In a setback to Gilead Sciences (GILD), a federal panel rejected its bid to invalidate a pair of patents owned by the U.S. government for using the Truvada pill to prevent HIV, a drug that has sparked controversy due to its cost and the extent to which taxpayer dollars funded crucial research.

The Patent Trial and Appeals Board ruled that Gilead failed to demonstrate it was likely to win its argument for overturning the patents held by the Centers for Disease Control and Prevention, which helped fund academic work into HIV prevention that later formed the basis for the best-selling medicine that is also known as PrEP (here is one ruling and here is the other).

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • If there’s a newsletter or continuous information on your pharma reporting please subscribe me. Thanks for your reporting.

  • I am going to side with the gov’t on this one. HIV medicine is very expensive. I think I read somewhere, that yearly it can cost 80K. This is another reason the insurance premium goes up. If cost can be lowered for HIV patient, that is good.

    On the side, Gilead is working with China on remdevisir for treating corona virus. And now China’s Wuhan Institute of Virology applied for a patent for the remdevisir. Talk about a dog biting the hand that feeds it.

    In the next epidemic outbreak in China, biotech company will think twice before stepping in to have their unlicensed medicine tested in China.

    Even if the reason given is national security, it is very shortsighted. Gilead invested money to developed remdevisir, and China can spend 1 billion US dollar without hurting itself to get access to that drug without biting the hands that is helping them. Another stupid decision from Wuhan.

    Maybe it is about time to get a new CEO and board for Gilead.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy